Cresset Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Cresset Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-457,666	Closed	-$15.3M	–	1108
2021 Q2	$15.3M	Hold	457,666	–	–	0.22%	43
2021 Q1	$9.43M	Hold	457,666	–	–	0.15%	57
2020 Q4	$8.02M	Hold	457,666	–	–	0.13%	63
2020 Q3	$6.79M	Hold	457,666	–	–	0.13%	72
2020 Q2	$5.95M	Hold	457,666	–	–	0.13%	73
2020 Q1	$760K	Hold	457,666	–	–	0.02%	230
2019 Q4	$1.02M	Hold	457,666	–	–	0.03%	204
2019 Q3	$975K	Hold	457,666	–	–	0.03%	189
2019 Q2	$1.23M	Buy	+457,666	New	+$1.55M	0.04%	157
2019 Q1	–	Sell	-457,667	Closed	-$1.36M	–	1998
2018 Q4	$1.36M	Buy	+457,667	New	+$2.25M	0.08%	55

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Cresset Asset Management's CLDX Position: Q3 2021 in Review

Cresset Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 457,666 shares — an estimated $15.3M sold.

Cresset Asset Management first reported a position in CLDX in Q4 2018 and held it in 10 quarters. The position peaked at $15.3M in Q2 2021. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

Cresset Asset Management reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
Cresset Asset Management sold 457,666 Celldex Therapeutics shares in Q3 2021, an estimated $15.3M.
Cresset Asset Management first reported a position in Celldex Therapeutics in Q4 2018 and held it in 10 quarters.
Cresset Asset Management's Celldex Therapeutics position peaked at $15.3M in Q2 2021.
160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on Cresset Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.